Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

41. Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS)

Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS) Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS) | Nagi | British Journal of Diabetes Font Size User Username Password Remember me Click for EXTOD PEAK 2019 Conference 18th October 2019, Glasgow ABCD Autumn Meeting 2019 28 / 29 (...) November 2019, London All issues 2014-present Browse Search All issues from 2014 Refine 2001-2013 at OR View listing of all 2001-2013 issues . Click on the issue you want to view it at About The Authors Dinesh Nagi Clare Hambling Roy Taylor Hosted By Part of the > > Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS) Dinesh Nagi, Clare Hambling, Roy Taylor Abstract This joint Association

2019 Association of British Clinical Diabetologists

42. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes (Abstract)

Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes The 2019 Standards of Medical Care in Diabetes suggested that patients with nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis. However, the performance of noninvasive clinical models/scores and plasma biomarkers for the diagnosis of nonalcoholic steatohepatitis (NASH) and advanced fibrosis has not been carefully assessed (...) in patients with type 2 diabetes mellitus (T2DM).In this cross-sectional study, patients (n = 213) had a liver MRS, and those with a diagnosis of NAFLD underwent a percutaneous liver biopsy. Several noninvasive clinical models/scores and plasma biomarkers were measured to identify NASH and advanced fibrosis (NASH: ALT, cytokeratin-18, NashTest 2, HAIR, BARD, and OWLiver; advanced fibrosis: AST, fragments of propeptide of type III procollagen [PRO-C3], FIB-4, APRI, NAFLD fibrosis score, and FibroTest).None

2019 EvidenceUpdates

43. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial (Abstract)

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial Existing guidelines for management of type 2 diabetes recommend a patient-centred approach to guide the choice of pharmacological agents. Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly used as second-line agents, direct (...) comparisons between these treatments are insufficient. In the SUSTAIN 8 trial, we compared the efficacy and safety of semaglutide (a GLP-1 receptor agonist) with canagliflozin (an SGLT2 inhibitor) in patients with type 2 diabetes.This was a double-blind, parallel-group, phase 3b, randomised controlled trial done at 111 centres in 11 countries. Eligible patients were at least 18 years old and had uncontrolled type 2 diabetes (HbA1c 7·0-10·5% [53-91 mmol/mol]) on stable daily metformin therapy. Patients

2019 EvidenceUpdates

44. Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial (Abstract)

Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial We evaluated the safety and efficacy of day-and-night fully closed-loop insulin therapy using faster (Faster-CL) compared with standard insulin aspart (Standard-CL) in young adults with type 1 diabetes.In a double-blind, randomized, crossover trial, 20 participants with type 1 diabetes on insulin pump therapy (11 females, aged 21.3 (...) as the primary end point.The proportion of TIR was similar for both arms: 53.3% (83% overnight) in Faster-CL and 57.9% (88% overnight) in Standard-CL (P = 0.170). The proportion of time in hypoglycemia <70 mg/dL was 0.0% for both groups. Baseline-adjusted interstitial prandial glucose increments 1 h after meals were greater in Faster-CL compared with Standard-CL (P = 0.017). The gaps between measured plasma insulin and estimated insulin-on-board levels at the beginning, at the end, and 2 h after the exercise

2019 EvidenceUpdates

45. Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis Full Text available with Trip Pro

Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis To evaluate the comparative efficacy and safety of lixisenatide combined with basal insulin (BI) vs intensive premix insulin (premix), BI plus prandial insulin with the main meal (basal-plus) or progressively covering all meals (basal-bolus (...) ) in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by BI, and the long-term cost-effectiveness of lixisenatide from a Chinese healthcare system perspective.Randomized controlled trials (RCTs) published between 1998 and 2018 were systematically searched. The clinical efficacy and safety of each treatment were compared by network meta-analysis (NMA). The IQVIA CORE Diabetes Model was used to estimate the lifetime quality-adjusted life-years (QALYs) and direct medical costs of patients

2019 EvidenceUpdates

46. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis (Abstract)

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney failure, particularly the need for dialysis or transplantation or death due to kidney disease, is uncertain. Additionally, previous studies have been underpowered to robustly assess heterogeneity of effects on kidney outcomes by different levels of estimated glomerular filtration rate (eGFR (...) ) and albuminuria. We aimed to do a systematic review and meta-analysis to assess the effects of SGLT2 inhibitors on major kidney outcomes in patients with type 2 diabetes and to determine the consistency of effect size across trials and different levels of eGFR and albuminuria.We did a systematic review and meta-analysis of randomised, controlled, cardiovascular or kidney outcome trials of SGLT2 inhibitors that reported effects on major kidney outcomes in people with type 2 diabetes. We searched MEDLINE

2019 EvidenceUpdates

47. Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes (Abstract)

Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes To identify and synthesize phase 3 and phase 4 randomized controlled trials (RCTs) of sodium-glucose co-transporter (SGLT) inhibitors and metformin as adjuncts to insulin in type 1 diabetes (T1DM) using network meta-analysis (NMA).A systematic literature review (SLR) identified relevant RCTs of ≥12 Weeks duration. MEDLINE, Embase, the Cochrane (...) dapagliflozin (5 mg), sotagliflozin (200 mg) and empagliflozin (10 mg) had larger reductions in HbA1c (mean difference [MD] = -0.24, 95% credible interval [CrI], -0.41 to -0.07, MD = -0.23, 95% CrI, -0.39 to -0.08 and MD = -0.35, 95% CrI, -0.51 to -0.19, respectively) and in weight, which were sustained in sensitivity analyses. There were few differences observed in the results of safety outcomes, such as risk of diabetic ketoacidosis (DKA), which should be interpreted cautiously because of wide

2019 EvidenceUpdates

48. Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men Full Text available with Trip Pro

Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men Sodium-glucose co-transporter-2 (SGLT2) inhibitors prevent cardiovascular complications in type 2 diabetes. We aimed to study whether they have similar effects in women and men by summarizing the effects of SGLT2 inhibitors compared to placebo on vascular and safety outcomes stratified by sex. We included patients with type 2 diabetes enrolled in the EMPA-REG OUTCOME, CANVAS Program, DECLARE TIMI-58

2019 EvidenceUpdates

49. Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes (Abstract)

Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes Hepatic-directed vesicle insulin (HDV) uses a hepatocyte-targeting moiety passively attaching free insulin, improving subcutaneous insulin's hepatic biodistribution. We assessed HDV-insulin lispro (HDV-L) versus insulin lispro (LIS) in type 1 diabetes (T1D).Insulin Liver Effect (ISLE-1) was a 26-week, phase 2b, multicenter, randomized, double-blind, noninferiority trial.Among 176 (...) 2019 by the American Diabetes Association.

2019 EvidenceUpdates

50. Advances in β-cell replacement therapy for the treatment of type 1 diabetes. Full Text available with Trip Pro

Advances in β-cell replacement therapy for the treatment of type 1 diabetes. The main goal of treatment for type 1 diabetes is to control glycaemia with insulin therapy to reduce disease complications. For some patients, technological approaches to insulin delivery are inadequate, and allogeneic islet transplantation is a safe alternative for those patients who have had severe hypoglycaemia complicated by impaired hypoglycaemia awareness or glycaemic lability, or who already receive (...) immunosuppressive drugs for a kidney transplant. Since 2000, intrahepatic islet transplantation has proven efficacious in alleviating the burden of labile diabetes and preventing complications related to diabetes, whether or not a previous kidney transplant is present. Age, body-mass index, renal status, and cardiopulmonary status affect the choice between pancreas or islet transplantation. Access to transplantation is limited by the number of deceased donors and the necessity of immunosuppression. Future

2019 Lancet

51. Changing the landscape for type 1 diabetes: the first step to prevention. (Abstract)

Changing the landscape for type 1 diabetes: the first step to prevention. Over several decades, studies have described the progression of autoimmune diabetes, from the first appearance of autoantibodies until, and after, the diagnosis of clinical disease with hyperglycaemia and insulin dependence. Despite the improved management of type 1 diabetes with exogenous insulin, most patients do not meet clinical glycaemic goals, and diabetes remains an important medical problem that affects children (...) and adults. Clinical and preclinical studies have suggested strategies to prevent the diagnosis of type 1 diabetes in people at risk, but the outcomes of previous clinical trials have not met their primary endpoints of disease prevention or delay. The results from the TN-10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a FcR non-binding monoclonal antibody to CD3 in people at high risk for disease. This Series paper discusses how this clinical

2019 Lancet

52. Advances in technology for management of type 1 diabetes. (Abstract)

Advances in technology for management of type 1 diabetes. Technological advances have had a major effect on the management of type 1 diabetes. In addition to blood glucose meters, devices used by people with type 1 diabetes include insulin pumps, continuous glucose monitors, and, most recently, systems that combine both a pump and a monitor for algorithm-driven automation of insulin delivery. In the next 5 years, as many advances are expected in technology for the management of diabetes (...) as there have been in the past 5 years, with improvements in continuous glucose monitoring and more available choices of systems that automate insulin delivery. Expansion of the use of technology will be needed beyond endocrinology practices to primary-care settings and broader populations of patients. Tools to support decision making will also need to be developed to help patients and health-care providers to use the output of these devices to optimise diabetes management.Copyright © 2019 Elsevier Ltd. All

2019 Lancet

53. Drugs for Type 2 Diabetes: Second-Line Therapy Review Update

Drugs for Type 2 Diabetes: Second-Line Therapy Review Update Drugs for Type 2 Diabetes: Second-Line Therapy Review Update | CADTH.ca Find the information you need Drugs for Type 2 Diabetes: Second-Line Therapy Review Update Drugs for Type 2 Diabetes: Second-Line Therapy Review Update Published on: February 7, 2018 Project Number: TR0012-000 Product Line: Therapeutic Review Result type: Report For an update on the status of CADTH’s Therapeutic Review of Third-Line Drugs for Type 2 Diabetes (...) , please . CADTH undertook a project to assess the clinical and cost-effectiveness of new drugs for the treatment of patients with type 2 diabetes. These new drugs were in three classes: dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. As part of this project, recommendations from the CADTH Canadian Drug Expert Committee (CDEC) were developed. This project is an update to two large projects on pharmacotherapy

2019 CADTH - Therapeutic Review

54. Excess mortality and life expectancy of individuals with type 1 diabetes: a rapid review

REPORTING ON LIFE EXPECTANCY 15 3.2.1. Literature search 15 3.2.2. The Scottish registry-based cohort study by Livingstone et al. 15 3.2.3. The Swedish registry-based cohort study by Petrie et al 16 2 Excess mortality and life expectancy of individuals with type 1 diabetes KCE Report 314 3.2.4. The Australian registry-based cohort study by Huo et al.. 16 3.2.5. Consistency of the evidence in the Scottish, Swedish and Australian cohort studies 17 3.2.6. The Taiwanese longitudinal cohort study based (...) 6 Excess mortality and life expectancy of individuals with type 1 diabetes KCE Report 314 PAD Peripheral Artery Disease PICO(D) Patient, Intervention, Comparator, Outcome, (Design) PY, PYE Patient Years (of Exposure or follow-up): PY or PYE can be used interchangeably RF Risk Factor(s) RR Relative Risk SMR Standardized Mortality Ratio SR Systematic Review T1D Type 1 Diabetes T2D Type 2 Diabetes y Year YLL Years of Life Lost KCE Report 314 Excess mortality and life expectancy of individuals

2019 Belgian Health Care Knowledge Centre

55. Cardiovascular Outcome Trials for Type 2 Diabetes

Cardiovascular Outcome Trials for Type 2 Diabetes Cardiovascular Outcome Trials for Type 2 Diabetes | CADTH.ca CADTH Document Viewer Cardiovascular Outcome Trials for Type 2 Diabetes Table of Contents Search this document Cardiovascular Outcome Trials for Type 2 Diabetes June 2019 Summary Dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists are classes of medications used in diabetes mellitus (DM (...) ) to improve glycemic control in people with type 2 diabetes mellitus (T2DM). Evidence from cardiovascular outcome trials (CVOT) is available for a number of medications; CVOTs are still in progress or have yet to be published for some others. The trials examined the addition of the medication in question to standard of care compared with placebo in patients with T2DM and established cardiovascular disease (CVD) or patients who are at high risk of cardiovascular (CV) events.The outcome measured

2019 CADTH - Issues in Emerging Health Technologies

56. Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Diabetic Nephropathy: A Review of Clinical Effectiveness

of Clinical Effectiveness Last updated: September 20, 2019 Project Number: RC1184-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of sodium glucose cotransporter 2 inhibitor for the treatment of diabetic nephropathy? Key Message Four systematic reviews and five randomized controlled trials on the clinical effectiveness of sodium glucose cotransporter 2 (SGLT2) inhibitors for treatment of adult patients (...) with type 2 diabetes and chronic kidney disease were identified.The risks for all-cause death, cardiovascular death, myocardial infarction, and stroke were less with SGLT2 inhibitor compared with placebo, however, the between group differences were not always statistically significant. The risk for heart failure was statistically significantly less with SGLT2 inhibitors compared with placebo.The risks for renal death, and end stage kidney disease was less with SGLT2 inhibitor compared with placebo

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

57. Reimbursement Status of Newer Drugs for the Treatment of Type 2 Diabetes

Reimbursement Status of Newer Drugs for the Treatment of Type 2 Diabetes Reimbursement Status of Newer Drugs for the Treatment of Type 2 Diabetes | CADTH.ca Find the information you need Reimbursement Status of Newer Drugs for the Treatment of Type 2 Diabetes Reimbursement Status of Newer Drugs for the Treatment of Type 2 Diabetes Last updated: February 27, 2019 Project Number: ES0337-000 Product Line: Result type: Report This project aims to retrieve and summarize the formulary status of drugs (...) pertaining to three classes used for the treatment of type 2 diabetes; i.e., dipeptidyl-peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide 1 (GLP-1) agonists. Information will be retrieved from the website of all publicly funded provincial, territorial, and federal drug plans in Canada. Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

58. Insulin degludec + liraglutide (Xultophy) - Diabetes mellitus, Type 2

Insulin degludec + liraglutide (Xultophy) - Diabetes mellitus, Type 2 insulin degludec + liraglutide | CADTH.ca Find the information you need insulin degludec + liraglutide insulin degludec + liraglutide Last Updated: October 3, 2019 Result type: Reports Project Number: SR0599-000 Product Line: Generic Name: insulin degludec + liraglutide Brand Name: Xultophy Manufacturer: Novo Nordisk Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria 1 (...) : To be reimbursed as an adjunct to lifestyle modifications to improve glycemic control in adults with type 2 diabetes mellitus when oral glucose-lowering medications combined with basal insulin, or basal insulin alone do not provide adequate glycemic control. Submission Type: New Combination Project Status: Active Biosimilar: No Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

59. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial (Abstract)

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial Fixed-ratio combinations of basal insulin plus glucagon-like peptide 1 receptor agonist (GLP-1 RA) allow concomitant administration of two proven complementary injectable therapies for type 2 diabetes. This study investigated switching to a titratable fixed-ratio combination of insulin glargine plus (...) lixisenatide (iGlarLixi) in patients with type 2 diabetes receiving daily or weekly GLP-1 RA therapy.LixiLan-G, a randomized, open-label, 26-week trial, compared switching to iGlarLixi versus continuing prior GLP-1 RA in patients with type 2 diabetes and HbA1c 7-9% (53-75 mmol/mol) taking maximum tolerated doses of a GLP-1 RA daily (60% on liraglutide once daily or exenatide twice daily) or weekly (40% on dulaglutide, exenatide extended release, or albiglutide) with metformin with or without pioglitazone

2019 EvidenceUpdates

60. Use of SGLT-2 inhibitors in the treatment of diabetes Full Text available with Trip Pro

Use of SGLT-2 inhibitors in the treatment of diabetes Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019) | Dashora | British Journal of Diabetes Font Size User Username Password Remember me Click for EXTOD PEAK 2019 Conference 18th October 2019, Glasgow ABCD Autumn Meeting 2019 28 / 29 November 2019, London All issues 2014-present Browse Search All issues from 2014 Refine 2001-2013 (...) at OR View listing of all 2001-2013 issues . Click on the issue you want to view it at About The Authors Umesh Dashora East Sussex Healthcare NHS Trust Dipesh C Patel Robert Gregory Peter Winocour Ketan Dhatariya Dinesh Nagi Hosted By Part of the > > Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019) Umesh Dashora, Dipesh C Patel, Robert Gregory, Peter Winocour, Ketan Dhatariya, Dinesh Nagi

2019 Association of British Clinical Diabetologists